Background—Endothelin-1 (ET-1) is a potent positive inotrope in vitro, but its physiological effects on intrinsic myocardial contractile function in humans in vivo are unknown. Plasma ET-1 levels are ...

Swiss pharma company Idorsia announced that its novel dual endothelin receptor antagonist (ERA), Tryvio (aprocitentan), has ...

The updated recommendations now include TRYVIO (aprocitentan) - the first and only hypertension treatment targeting the endothelin pathway.Endothelin is upregulated in hypertension and is a fundamenta ...

The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the ...

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Opsumit tablets, 10 mg, of ...

The Macitentan tablets, 10 mg, used to treat hypertension, have an estimated market size of $1,180 million for the 12 months till June 2025, as per IQVIA.

Investigators at St. John’s University have published preclinical data regarding their endothelin-1 receptor (ETRA) antagonist HJP-272 for the potential treatment of cancer.

A novel fluorescent photoprobe for the imaging of endothelin A receptors (ETAR) was developed. Based on the nonpeptidyl, high-affinity, and selective ETAR antagonist ...

In preclinical studies, endothelin receptor A (ETA) antagonists (ETAi) attenuated the progression of heart failure (HF). However, clinical HF trials failed to demonstrate beneficial effects of ETAi ...

Allschwil, Switzerland - August 12, 2025Idorsia Ltd (SIX: IDIA) announced today that The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, has nomina ...

What did we do? We looked for studies that compared endothelin receptor antagonist alone, phosphodiesterase type 5 inhibitor alone, or endothelin receptor antagonist plus phosphodiesterase type 5 ...